Enzo Biochem, Inc. (NYSE:ENZ) Short Interest Update

Enzo Biochem, Inc. (NYSE:ENZ) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 433,000 shares, a drop of 9.3% from the October 31st total of 477,500 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average trading volume of 86,700 shares, the days-to-cover ratio is presently 5.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Enzo Biochem in a report on Sunday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On Enzo Biochem

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the last quarter. BBR Partners LLC purchased a new position in Enzo Biochem during the third quarter worth $112,000. XTX Topco Ltd boosted its stake in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after acquiring an additional 64,417 shares during the period. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Price Performance

Shares of Enzo Biochem stock remained flat at $1.07 on Tuesday. 231,783 shares of the stock traded hands, compared to its average volume of 101,569. Enzo Biochem has a 52-week low of $0.93 and a 52-week high of $1.50. The company’s 50 day moving average price is $1.11 and its 200-day moving average price is $1.11.

Enzo Biochem Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 37.38%. The ex-dividend date of this dividend was Friday, November 15th.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.